Moderna, Inc. (MRNA)
Moderna, Inc. (MRNA) Moderna Oncology Investor Event (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Moderna Oncology Investor Event June 3, 2024 7:15 PM ET Company Participants Stephen Hoge - President Kyle Holen - Head of Development, Therapeutics and Oncology Michelle Brown - Vice President, INT Oncology Rose Loughlin - VP, R&D Strategy Lavina Talukdar - SVP & Head of IR Conference Call Participants Luca Issi - RBC Capital Markets Gena Wang - Barclays Dina Elmonshed - Jefferies Terence Flynn - Morgan Stanley Jess Fye - JPMorgan Myles Minter - William Blair Mani Foroohar - Leerink Partners Stephen Hoge We're going to get started. Thank you, everybody, for taking some time out of ASCO and your time here to spend with us.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
Moderna, Inc. (MRNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK, NY / ACCESSWIRE / June 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MRNA.
Moderna cancer vaccine's potential revealed in phase II data
Data from a key cancer conference has underlined the potential of a vaccine for melanoma that has now moved into late-stage clinical trials here in the UK. Last month, we heard of the first dosing of Moderna Inc (NASDAQ:MRNA, ETR:0QF)'s potential breakthrough jab for a phase III study that could offer hope for sufferers of skin cancer when used in combination with Merck's Keytruda, a checkpoint inhibitor therapy.
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
The RSV vaccine is Moderna???s (MRNA) second FDA-approved product.
Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
Moderna and Merck said their experimental vaccine in combination with the therapy Keytruda improved survival and showed durable efficacy in a midstage study in patients with a deadly form of skin cancer. Nearly 75% of patients who took the combination were alive without any signs or symptoms of their cancer returning at the 2½-year mark.
Moderna-Merck skin cancer vaccine shows survival benefit in long-term follow-up
Moderna and partner Merck & Co said on Monday their cancer vaccine in combination with blockbuster cancer therapy Keytruda improved survival and showed durable efficacy in a mid-stage study in patients with a deadly form of skin cancer.
Is Moderna Stock a Buy Now That It's a 2-Product Company?
Moderna earned approval for mResvia, a respiratory syncytial virus vaccine, on May 31. Instead of soaring in response to the great news, Moderna stock fell.
Moderna secures a second FDA vaccine approval as Spikevax sales plummet
Moderna announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its respiratory syncytial virus (RSV) vaccine for adults ages 60 and older. This will be the only RSV vaccine available in single-dose prefilled syringes and will be sold under the brand name mRESVIA.
Moderna Investors Just Got Some Bullish News
Moderna has brought in billions of dollars in earnings thanks to its coronavirus vaccine. But demand for that product has declined, and that has worried investors.
Moderna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA ) Bernstein's 40th Annual Strategic Decisions Conference May 31, 2024 10:00 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Courtney Breen - Bernstein Courtney Breen Hi, there, everyone. It's great to see you all on Friday of the conference.
Moderna wins second product approval with RSV vaccine
Moderna Inc.'s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved for a disease other than COVID-19.
